

Cardium Therapeutics, Inc.  
Form 8-K  
May 22, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**DATE OF REPORT (Date of earliest event reported): May 16, 2007**

**000-14136**

(Commission file number)

**CARDIUM THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of incorporation)

**27-0075787**  
(IRS Employer Identification No.)

**3611 Valley Centre Drive, Suite 525**  
**San Diego, California 92130**  
(Address of principal executive offices)

**(858) 436-1000**  
(Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 8.01 OTHER EVENTS.**

On May 16, 2007, Cardium Therapeutics, Inc., a Delaware corporation ( Cardium ), issued a press release announcing that Innercool Therapies, Inc. ( InnerCool ), its wholly-owned subsidiary, would be presenting InnerCool s two next-generation medical device systems designed to provide comprehensive solutions to patient temperature modulation at the upcoming Symposium on Neurological Emergencies & Neurological Care on May 25, 2007 at the New York Academy of Medicine in New York City, New York.

Also on May 16, 2007, Cardium issued a second press release announcing the start of patient recruitment for its Phase 3 clinical trial (AWARE) to evaluate the therapeutic effects of its lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), in women for the potential treatment of myocardial ischemia.

Copies of the press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2 and incorporated by reference herein.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

99.1 Press Release dated May 16, 2007, of Cardium relating to InnerCool s two next-generation medical devise systems.

99.2 Press Release dated May 16, 2007, of Cardium relating to the initiation of its Phase 3 AWARE clinical study for Generx.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARDIUM THERAPEUTICS, INC.**

Date: May 22, 2007

By: /s/ Christopher J. Reinhard  
**Christopher J. Reinhard**  
**Chief Executive Officer**